Asthma Therapeutics Market Outlook, Strategies And Forecasts, Competitive analysis & Industry Trends

The research report identifies the key driving factors of the asthma therapeutics market as the rising environmental pollution that adversely affects the respiratory system of the human body, causing asthma and other respiratory diseases. Rapidly growing industrialization and globalization have led to an imbalance in the environmental constitution.

One of the most conspicuous trends in this market is the adoption of a combination of therapies for the treatment of asthma patients. This technique can further help asthma patients by controlling inflammation caused in the respiratory tract. However, the biggest challenge faced by the drug producers is the etiology of respiratory diseases owing to which developing the remedy becomes a tough job.

Read Complete Report @ http://www.mrrse.com/asthma-therapeutics-market

Some of the key players of the global asthma therapeutics market are GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, AstraZeneca plc, and F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc (GSK) is the topmost seller of drugs of the of the global asthma therapeutics market. The British multinational company which was formed in 2000 is the largest drug and vaccine manufacturer for major diseases such as infections, digestive, asthma, mental health conditions, diabetes, and cancer.

Advair – an eminent asthma therapeutic product is the highly selling drug which is manufactured by GlaxoSmithKline plc. After Advair, the Symbicort drug manufactured by AstraZeneca holds the second position in selling asthma drugs in the global asthma therapeutics market.

Get a Free Sample Copy of the Report @ http://www.mrrse.com/sample/106

Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.5 Symptoms
2.6 Diagnosis
2.7 Assessment of Disease Severity
2.8 Treatment
2.9 Treatment Algorithm
2.10 Treatment Segments
2.10.1 ICS Monotherapy for the Maintenance Treatment of Asthma
2.10.2 Singulair (montelukast sodium) as First-Line Maintenance Therapy
2.10.3 ICS/LABA Combination Therapy
2.10.4 Add-on Therapies

3 Marketed Products
3.1 Overview
3.2 ICS for the Maintenance Treatment of Asthma
3.2.1 Arnuity (fluticasone furoate) – GSK
3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma
3.3.1 Advair (fluticasone propionate and salmeterol xinafoate) – GSK
3.3.2 Symbicort (budesonide and formoterol fumarate) – AstraZeneca, Co-Promotion with Astellas Pharma
3.3.3 Dulera (mometasone furoate and formoterol fumarate) – Merck
3.3.4 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) – GlaxoSmithKline/Theravance
3.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma
3.4.1 Xolair (omalizumab) – Novartis and Genentech
3.4.2 Singulair (montelukast) – Merck
3.4.3 Spiriva (tiotropium bromide) – Boehringer Ingelheim
3.5 Heat Maps for Marketed Products

About MRRSE

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Contact

Mr.Nachiket Ghumare
Corporate Office
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-730-0559
Email: sales@mrrse.com

This release was published on openPR.